All In Biotech

Drug Trial Radar · NCT06192108

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 962 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

962

Actual

Start

Jan 10, 2024

Primary completion

Sep 26, 2025

Study completion Sep 26, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.

Conditions

  • Type 2 Diabetes

Interventions

  • OrforglipronDrug

    Administered orally

  • DapagliflozinDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c [Noninferiority Analysis]Time frame: Baseline, Week 40

Locations

74 sites in 6 countries. Site status is shown where the registry gives one.

  • Alliance Research Institute - Canoga Park

    Canoga Park, California

  • Ark Clinical Research

    Long Beach, California

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California

  • Wolverine Clinical Trials

    Santa Ana, California

  • CMR of Greater New Haven, LLC

    Hamden, Connecticut

  • Institute of Endocrinology Diabetes, Health & Hormone

    Stockbridge, Georgia

  • Elite Clinical Trials

    Rexburg, Idaho

  • Accellacare - DuPage

    Lombard, Illinois

  • Tandem Clinical Research

    Marrero, Louisiana

  • St. Vincent Healthcare

    Billings, Montana

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico

  • Accellacare - Winston-Salem

    Winston-Salem, North Carolina

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma

  • Essential Medical Research

    Tulsa, Oklahoma

  • Accellacare - Mt Pleasant

    Mt. Pleasant, South Carolina

  • Accellacare, US Inc., d/b/a Accellacare of Knoxville

    Jefferson City, Tennessee

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Juno Research

    Houston, Texas

  • Consano Clinical Research, LLC

    Shavano Park, Texas

  • The Second People's Hospital of Hefei

    Hefei, Anhui, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • Diabetes Zentrum Wilhelmsburg

    Hamburg, Germany

  • CRS Clinical Research Services Mannheim

    Mannheim, Baden-Wurttemberg, Germany

  • Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz

    Lingen, Lower Saxony, Germany

  • Diabetes- und Stoffwechselpraxis Bochum

    Bochum, North Rhine-Westphalia, Germany

  • Zentrum fur klinische Forschung - Köln

    Cologne, North Rhine-Westphalia, Germany

  • InnoDiab Forschung Gmbh

    Essen, North Rhine-Westphalia, Germany

  • Medizentrum Essen Borbeck

    Essen, North Rhine-Westphalia, Germany

  • Institut für Diabetesforschung GmbH Münster

    Münster, North Rhine-Westphalia, Germany

  • Praxis Dr. Veronika Wenzl-Bauer

    Rehlingen, Saarland, Germany

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.